• Have a diagnosis of active psoriatic arthritis (PsA) as defined by a rheumatologist or other healthcare professional (HCP) experienced in treating PsA.

• Body Mass Index (BMI) of 30 kilograms per meter squared (kg/m²) or greater (obesity) or 27 kg/m2 to \<30 kg/m² (overweight) in the presence of at least 1 weight-related comorbid condition (hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, or cardiovascular disease).

• Who have been treated with ixekizumab for approximately 3 months (±1 month) prior to decision to add tirzepatide.

• Must be able to initiate tirzepatide (Day 0) within 30 days of treatment decision (baseline or screening).